Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03505723




Registration number
NCT03505723
Ethics application status
Date submitted
16/03/2018
Date registered
23/04/2018
Date last updated
21/08/2023

Titles & IDs
Public title
PeriOperative ISchemic Evaluation-3 Trial
Scientific title
PeriOperative ISchemic Evaluation-3 Trial
Secondary ID [1] 0 0
2018.02.08
Universal Trial Number (UTN)
Trial acronym
POISE-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Perioperative Bleeding 0 0
Venous Thrombosis 0 0
Arterial Thrombosis 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Blood 0 0 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tranexamic Acid
Treatment: Drugs - Placebo (Saline)
Other interventions - Perioperative hypotension-avoidance strategy
Other interventions - Perioperative hypertension-avoidance strategy

Active comparator: Tranexamic Acid (TXA) - Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).

Placebo comparator: Placebo (0.9% normal saline) - Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).

Active comparator: Hypotension-avoidance strategy - Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).

Placebo comparator: Perioperative hypertension-avoidance strategy - Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).


Treatment: Drugs: Tranexamic Acid
Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.

Treatment: Drugs: Placebo (Saline)
Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.

Other interventions: Perioperative hypotension-avoidance strategy
Perioperative hypotension-avoidance strategy includes:

1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP =130 mm Hg before surgery,
2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) =80 mm Hg
3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP =130 mm Hg during the first 48 hours after surgery.

Other interventions: Perioperative hypertension-avoidance strategy
Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP =60 mm Hg.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
A composite of life-threatening bleeding, major bleeding, and critical organ bleeding
Timepoint [1] 0 0
30 days after randomization
Primary outcome [2] 0 0
A composite of MINS, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism.
Timepoint [2] 0 0
30 days after randomization
Primary outcome [3] 0 0
For patients in the blood pressure management arm: A composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest.
Timepoint [3] 0 0
30 days after randomization
Secondary outcome [1] 0 0
A net risk-benefit outcome as a composite of vascular death, and non-fatal life-threatening,major or critical organ bleeding,MINS,stroke,peripheral arterial thrombosis,and symptomatic proximal venous thromboembolism
Timepoint [1] 0 0
30 days after randomization
Secondary outcome [2] 0 0
BIMS
Timepoint [2] 0 0
30 days after randomization
Secondary outcome [3] 0 0
MINS
Timepoint [3] 0 0
30 days after randomization
Secondary outcome [4] 0 0
MINS not fulfilling the universal definition of myocardial infarction
Timepoint [4] 0 0
30 days after randomization
Secondary outcome [5] 0 0
Myocardial infarction
Timepoint [5] 0 0
30 days after randomization
Secondary outcome [6] 0 0
For patients in the blood pressure management arm: all-cause mortality
Timepoint [6] 0 0
30 days after randomization
Secondary outcome [7] 0 0
For patients in the blood pressure management arm: MINS
Timepoint [7] 0 0
30 days after randomization
Secondary outcome [8] 0 0
For patients in the blood pressure management arm: Myocardial infarction
Timepoint [8] 0 0
30 days after randomization
Secondary outcome [9] 0 0
For patients in the blood pressure management arm: MINS not fulfilling the universal definition of myocardial infarction
Timepoint [9] 0 0
30 days after randomization

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Undergoing noncardiac surgery;
2. = 45 years of age;
3. Expected to require at least an overnight hospital admission after surgery;
4. Provide written informed consent to participate in the POISE-3 Trial, AND
5. Fulfill =1 of the following 6 criteria (A-F):

A. NT-proBNP =200 ng/L B. History of coronary artery disease C. History of peripheral arterial disease D. History of stroke E. Undergoing major vascular surgery; OR F. Any 3 of 9 risk criteria i. Undergoing major surgery; ii. History of congestive heart failure; iii. History of a transient ischemic attack; iv. Diabetes and currently taking an oral hypoglycemic agent or insulin; v. Age >70 years; vi. History of hypertension; vii. Serum creatinine > 175 µmol/L (> 2.0 mg/dl); viii. History of smoking within 2 years of surgery; ix. Undergoing emergent/urgent surgery.
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion criteria:

1. Patients undergoing cardiac surgery
2. Patients undergoing cranial neurosurgery
3. Planned use of systemic TXA during surgery
4. Low-risk surgical procedure (based on individual physician's judgment)
5. Hypersensitivity or known allergy to TXA
6. Creatinine clearance <30 mL/min (Cockcroft-Gault equation) or on chronic dialysis
7. History of seizure disorder
8. Patients with recent stroke, myocardial infarction, acute arterial thrombosis or venous thromboembolism (<3 month)
9. Patients with fibrinolytic conditions following consumption coagulopathy
10. Patients with subarachnoid hemorrhage within the past 30 days
11. Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
12. Previously enrolled in POISE-3 Trial

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Factorial
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/06/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
3/02/2023
Sample size
Target
Accrual to date
Final
9535
Recruitment in Australia
Recruitment state(s)
QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Queen Elizabeth II Jubilee Hospital - Brisbane
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [5] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [6] 0 0
Eastern Health (Box Hill Hospital) - Box Hill
Recruitment hospital [7] 0 0
Dandenong Hospital - Dandenong
Recruitment hospital [8] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [9] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [10] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [11] 0 0
Western Health - Footscray
Recruitment hospital [12] 0 0
Peter MacCallum Hospital - Melbourne
Recruitment hospital [13] 0 0
John Hunter Hospital - New Lambton
Recruitment hospital [14] 0 0
Royal Perth - Perth
Recruitment hospital [15] 0 0
Princes of Wales Hospital - Randwick
Recruitment hospital [16] 0 0
Goulburn Valley Health - Shepparton
Recruitment hospital [17] 0 0
Westmead Hospital - Sydney
Recruitment postcode(s) [1] 0 0
4108 - Brisbane
Recruitment postcode(s) [2] 0 0
- Woolloongabba
Recruitment postcode(s) [3] 0 0
- Adelaide
Recruitment postcode(s) [4] 0 0
- Bedford Park
Recruitment postcode(s) [5] 0 0
- Hobart
Recruitment postcode(s) [6] 0 0
- Box Hill
Recruitment postcode(s) [7] 0 0
- Dandenong
Recruitment postcode(s) [8] 0 0
- Heidelberg
Recruitment postcode(s) [9] 0 0
- Parkville
Recruitment postcode(s) [10] 0 0
- Murdoch
Recruitment postcode(s) [11] 0 0
- Footscray
Recruitment postcode(s) [12] 0 0
- Melbourne
Recruitment postcode(s) [13] 0 0
- New Lambton
Recruitment postcode(s) [14] 0 0
- Perth
Recruitment postcode(s) [15] 0 0
- Randwick
Recruitment postcode(s) [16] 0 0
- Shepparton
Recruitment postcode(s) [17] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Connecticut
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
United States of America
State/province [4] 0 0
North Carolina
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon
Country [7] 0 0
United States of America
State/province [7] 0 0
Rhode Island
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Austria
State/province [9] 0 0
Vienna
Country [10] 0 0
Belgium
State/province [10] 0 0
Brussels
Country [11] 0 0
Brazil
State/province [11] 0 0
Minas Gerais
Country [12] 0 0
Brazil
State/province [12] 0 0
Porto Alegre
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
Manitoba
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Canada
State/province [17] 0 0
Saskatchewan
Country [18] 0 0
Canada
State/province [18] 0 0
London
Country [19] 0 0
Chile
State/province [19] 0 0
Santiago
Country [20] 0 0
Chile
State/province [20] 0 0
Temuco
Country [21] 0 0
China
State/province [21] 0 0
Anhui
Country [22] 0 0
China
State/province [22] 0 0
Guangdong
Country [23] 0 0
China
State/province [23] 0 0
Heilongjiang
Country [24] 0 0
China
State/province [24] 0 0
Sichuan
Country [25] 0 0
Denmark
State/province [25] 0 0
Capital Region
Country [26] 0 0
Denmark
State/province [26] 0 0
Copenhagen
Country [27] 0 0
Denmark
State/province [27] 0 0
Køge
Country [28] 0 0
France
State/province [28] 0 0
Paris
Country [29] 0 0
Germany
State/province [29] 0 0
Aachen
Country [30] 0 0
Germany
State/province [30] 0 0
Bonn
Country [31] 0 0
Germany
State/province [31] 0 0
Dortmund
Country [32] 0 0
Germany
State/province [32] 0 0
Düsseldorf
Country [33] 0 0
Hong Kong
State/province [33] 0 0
Sha Tin
Country [34] 0 0
India
State/province [34] 0 0
Gujarat
Country [35] 0 0
India
State/province [35] 0 0
Gujurat
Country [36] 0 0
India
State/province [36] 0 0
Karnataka
Country [37] 0 0
India
State/province [37] 0 0
Kerala
Country [38] 0 0
India
State/province [38] 0 0
Maharashtra
Country [39] 0 0
India
State/province [39] 0 0
Punjab
Country [40] 0 0
India
State/province [40] 0 0
Uttar Pradesh
Country [41] 0 0
India
State/province [41] 0 0
West Bengal
Country [42] 0 0
India
State/province [42] 0 0
Alappuzha
Country [43] 0 0
India
State/province [43] 0 0
Bangalore
Country [44] 0 0
Italy
State/province [44] 0 0
Genova
Country [45] 0 0
Italy
State/province [45] 0 0
Milano
Country [46] 0 0
Italy
State/province [46] 0 0
Milan
Country [47] 0 0
Malaysia
State/province [47] 0 0
Negeri Sembilan
Country [48] 0 0
Malaysia
State/province [48] 0 0
Sarawak
Country [49] 0 0
Malaysia
State/province [49] 0 0
Kuala Lumpur
Country [50] 0 0
Malaysia
State/province [50] 0 0
Pulau Pinang
Country [51] 0 0
Malaysia
State/province [51] 0 0
Sungai Buloh
Country [52] 0 0
Netherlands
State/province [52] 0 0
Overijssel
Country [53] 0 0
Netherlands
State/province [53] 0 0
Rotterdam
Country [54] 0 0
New Zealand
State/province [54] 0 0
Auckland
Country [55] 0 0
New Zealand
State/province [55] 0 0
Hamilton
Country [56] 0 0
Pakistan
State/province [56] 0 0
Islamabad Capital Territory
Country [57] 0 0
Pakistan
State/province [57] 0 0
Karachi
Country [58] 0 0
Poland
State/province [58] 0 0
Kraków
Country [59] 0 0
Poland
State/province [59] 0 0
Tarnów
Country [60] 0 0
Poland
State/province [60] 0 0
Zielona Góra
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Arkhangelsk
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Moscow
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Novosibirsk
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Saint Petersburg
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Tyumen
Country [66] 0 0
South Africa
State/province [66] 0 0
Cape Town
Country [67] 0 0
South Africa
State/province [67] 0 0
Gauteng
Country [68] 0 0
Spain
State/province [68] 0 0
Barcelona
Country [69] 0 0
Spain
State/province [69] 0 0
Girona
Country [70] 0 0
Spain
State/province [70] 0 0
Madrid
Country [71] 0 0
Spain
State/province [71] 0 0
Valladolid
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Gillingham
Country [73] 0 0
United Kingdom
State/province [73] 0 0
London

Funding & Sponsors
Primary sponsor type
Other
Name
Population Health Research Institute
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy.
Trial website
https://clinicaltrials.gov/study/NCT03505723
Trial related presentations / publications
Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Borges FK, Martinez-Zapata MJ, Wang CY, Xavier D, Ofori SN, Wang MK, Efremov S, Landoni G, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Duceppe E, Ruetzler K, Parlow JL, Tandon V, Fleischmann E, Polanczyk CA, Lamy A, Astrakov SV, Rao M, Wu WKK, Bhatt K, de Nadal M, Likhvantsev VV, Paniagua P, Aguado HJ, Whitlock RP, McGillion MH, Prystajecky M, Vincent J, Eikelboom J, Copland I, Balasubramanian K, Turan A, Bangdiwala SI, Stillo D, Gross PL, Cafaro T, Alfonsi P, Roshanov PS, Belley-Cote EP, Spence J, Richards T, VanHelder T, McIntyre W, Guyatt G, Yusuf S, Leslie K; POISE-3 Investigators. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022 May 26;386(21):1986-1997. doi: 10.1056/NEJMoa2201171. Epub 2022 Apr 2.
Marcucci M, Painter TW, Conen D, Leslie K, Lomivorotov VV, Sessler D, Chan MTV, Borges FK, Martinez Zapata MJ, Wang CY, Xavier D, Ofori SN, Landoni G, Efremov S, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Duceppe E, Ruetzler K, Parlow JL, Tandon V, Wang MK, Fleischmann E, Polanczyk CA, Jayaram R, Astrakov SV, Rao M, VanHelder T, Wu WKK, Cheong CC, Ayad S, Abubakirov M, Kirov M, Bhatt K, de Nadal M, Likhvantsev V, Iglesisas PP, Aguado HJ, McGillion M, Lamy A, Whitlock RP, Roshanov P, Stillo D, Copland I, Vincent J, Balasubramanian K, Bangdiwala SI, Biccard B, Kurz A, Srinathan S, Petit S, Eikelboom J, Richards T, Gross PL, Alfonsi P, Guyatt G, Belley-Cote E, Spence J, McIntyre W, Yusuf S, Devereaux PJ. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 2022 Jan 31;23(1):101. doi: 10.1186/s13063-021-05992-1.
Public notes

Contacts
Principal investigator
Name 0 0
PJ Devereaux, MD, PhD
Address 0 0
Hamilton Health Sciences Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03505723